ArticleJHEP reports : innovation in hepatology2026

Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC.

Najib Ben Khaled et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.